GlaxoSmithKline Accused Of Burying Negative Paxil Studies & Keeping Info From FDA
GlaxoSmithKline (GSK) executives are being accused of burying negative studies on the company’s antidepressant drug, Paxil, and its link to birth defects – from consumers and the U.S. Food and Drug Adminstration (FDA). The allegations are likely to have a very damaging effect on the pharmaceutical giant as Paxil litigation begins in the United States.
→ Read More